Development of Multivalent Vaccines Against Yellow Fever and Arena Viruses

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$599,895.00
Award Year:
2010
Program:
SBIR
Phase:
Phase I
Contract:
1R43AI084350-01A1
Award Id:
95728
Agency Tracking Number:
AI084350
Solicitation Year:
n/a
Solicitation Topic Code:
NIAID
Solicitation Number:
n/a
Small Business Information
BIOPROTECTION SYSTEMS CORPORATION, 2901 S LOOP DR, STE 3360, AMES, IA, -
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
606727076
Principal Investigator:
RAMON FLICK
(515) 296-3944
RFLICK@BPSYS.NET
Business Contact:
CARL LANGREN
() -
clangren@bpsys.net
Research Institute:
n/a
Abstract
DESCRIPTION (provided by applicant): Indigenous population, travelers and troops present in Africa and South America are clearly at risk of exposure to several arenaviruses. Several human pathogenic arenaviruses, e.g., Lassa and Junin viruses, are listed o n the NIAID's Priority Pathogens and CDC's Bioterrorism Agents Lists and can cause a deadly hemorrhagic fever. No effective and safe vaccine is currently available to combat these diseases. In addition, effective arenavirus vaccines are needed for the Stra tegic National Stockpile in preparation for a potential bioterror attack in the United States. A commonly used, safe vaccine platform based on the Yellow fever (YF) vaccine 17D will be exploited to generate a protective vaccine against arenaviral infection s. The live-attenuated YF-17D virus vaccine strain has been used for human immunization since 1936. More than 500 million people have been vaccinated with YF-17D over the past 70 years, and the vaccine has a truly remarkable record of safety and efficacy. A single subcutaneous immunization with YF-17D elicits long-lasting protective antibodies and cellular immune responses. We will use this vaccine platform to generate multivalent arenavirus vaccines protecting against YFV and different arenaviruses. This new vaccine approach represents an important upgrade/replacement for the standard YF-17D vaccine that will provide immunity to both YF and important arenaviruses. Besides the overall known safety of the vaccine platform, the published proof of concept for the use of this platform to protect against a deadly arenavirus, and the advantage of targeting different viral diseases in a similar geographical location (e.g., YF and Lassa fever - Lassa virus in West Africa; YF and Argentine hemorrhagic fever- Junmn v irus in South America) makes this approach ideal as a prophylactic treatment for protecting indogenous populations, travelers and warfighters. Importantly, the multivalent YF-17D vaccine platform is readily adaptable for the generation of immunity to othe r viral families, such as bunyaviruses (Rift Valley fever virus, Crimean-Congo hemorrhagic fever virus) and henipaviruses (Nipah virus, Hendra virus), all of which present (i) a real threat to the indigenous populations and travelers in locations including Africa, Middle East and Southeast Asia, and (ii) a bioterror threat to the United States and its allies. PUBLIC HEALTH RELEVANCE: Yellow fever viruses and arenaviruses (e.g., Junin, Lassa) that cause hemorrhagic fever (HF) are serious health concer ns - as emerging diseases as well as bioterror threats. We will use the safe and approved Yellow Fever 17D vaccine as a platform to develop a multivalent Yellow fever-arenavirus vaccine. This new multivalent vaccine will simultaneously protect against seve ral hemorrhagic fever-causing pathogens.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government